DarioHealth Expands GLP-1 Solution with Prescribing Capabilities through Collaboration with MediOrbis, Targeting Employers and Direct-to-Consumer Markets
DarioHealth (Nasdaq: DRIO) has announced a strategic collaboration with MediOrbis to enhance its GLP-1 behavior change solution by adding prescribing capabilities. This partnership creates a comprehensive medical weight loss program targeting employers and direct-to-consumer markets.
The collaboration comes as employer coverage of GLP-1 medications for weight loss expands, with 44% of large employers now covering obesity drugs according to a Mercer survey. The enhanced solution aims to ensure appropriate prescription of medications while providing behavior change support for sustainable weight loss outcomes.
The partnership positions Dario to drive recurring revenue through multiple channels, including employer-sponsored programs and direct-to-consumer offerings. The integrated solution combines virtual physician management with Dario's behavior change expertise to optimize outcomes and ROI for employers, while providing seamless access to care for individuals most likely to benefit from GLP-1 medications.
DarioHealth (Nasdaq: DRIO) ha annunciato una collaborazione strategica con MediOrbis per migliorare la sua soluzione di cambiamento del comportamento GLP-1 aggiungendo funzionalità di prescrizione. Questa partnership crea un programma medico completo per la perdita di peso rivolto a datori di lavoro e mercati diretti al consumatore.
La collaborazione arriva mentre la copertura da parte dei datori di lavoro dei farmaci GLP-1 per la perdita di peso si sta espandendo, con il 44% dei grandi datori di lavoro che coprono attualmente i farmaci per l'obesità, secondo un sondaggio di Mercer. La soluzione potenziata mira a garantire la prescrizione appropriata dei farmaci fornendo al contempo supporto per il cambiamento del comportamento per risultati di perdita di peso sostenibili.
La partnership colloca Dario nella posizione di generare entrate ricorrenti attraverso più canali, inclusi programmi sponsorizzati dai datori di lavoro e offerte dirette al consumatore. La soluzione integrata combina la gestione virtuale dei medici con l'expertise di Dario nel cambiamento del comportamento per ottimizzare i risultati e il ritorno sugli investimenti per i datori di lavoro, garantendo al tempo stesso un accesso fluido alle cure per le persone che potrebbero trarre maggiore beneficio dai farmaci GLP-1.
DarioHealth (Nasdaq: DRIO) ha anunciado una colaboración estratégica con MediOrbis para mejorar su solución de cambio de comportamiento GLP-1 añadiendo capacidades de prescripción. Esta asociación crea un programa médico integral de pérdida de peso que se dirige a empleadores y mercados de consumidor directo.
La colaboración se produce mientras la cobertura de medicamentos GLP-1 para la pérdida de peso por parte de los empleadores se expande, con un 44% de los grandes empleadores ahora cubriendo fármacos para la obesidad, según una encuesta de Mercer. La solución mejorada tiene como objetivo garantizar la prescripción adecuada de medicamentos, al tiempo que proporciona apoyo para el cambio de comportamiento para resultados sostenibles en la pérdida de peso.
La asociación posiciona a Dario para generar ingresos recurrentes a través de múltiples canales, incluidos programas patrocinados por empleadores y ofertas directas al consumidor. La solución integrada combina la gestión virtual de médicos con la experiencia de Dario en cambio de comportamiento para optimizar resultados y retorno de la inversión para los empleadores, mientras proporciona un acceso fluido a la atención para las personas que más probablemente se beneficiarán de los medicamentos GLP-1.
DarioHealth (Nasdaq: DRIO)는 MediOrbis와의 전략적 협력을 발표하여 GLP-1 행동 변화 솔루션에 처방 기능을 추가했습니다. 이 파트너십은 고용주 및 소비자 직접 시장을 대상으로 하는 포괄적인 의료 체중 감량 프로그램을 만듭니다.
이번 협력은 고용주들이 체중 감소를 위한 GLP-1 약물의 보장을 확대하면서 이루어졌으며, 머서(Mercer) 조사에 따르면 대규모 고용주 중 44%가 현재 비만 약물을 보장하고 있습니다. 향상된 솔루션은 지속 가능한 체중 감소 결과를 위한 행동 변화 지원을 제공하면서 약물의 적절한 처방을 보장하는 것을 목표로 합니다.
이 파트너십은 Dario가 고용주 후원 프로그램과 소비자 직접 제공을 포함한 여러 채널을 통해 반복 수익을 창출할 수 있는 위치를 제공합니다. 통합 솔루션은 가상 의사 관리와 Dario의 행동 변화 전문성을 결합하여 고용주에게 결과 및 투자 수익을 최적화하고, GLP-1 약물의 혜택을 받을 가능성이 가장 높은 개인에게 원활한 치료 접근을 제공합니다.
DarioHealth (Nasdaq: DRIO) a annoncé une collaboration stratégique avec MediOrbis pour améliorer sa solution de changement de comportement GLP-1 en ajoutant des capacités de prescription. Ce partenariat crée un programme médical complet de perte de poids ciblant les employeurs et les marchés en direct-consommateur.
Cette collaboration arrive alors que la couverture des médicaments GLP-1 pour la perte de poids par les employeurs s'étend, avec 44 % des grandes entreprises couvrant actuellement les médicaments contre l'obésité, selon une enquête de Mercer. La solution améliorée vise à garantir la prescription appropriée des médicaments tout en fournissant un soutien au changement de comportement pour des résultats de perte de poids durables.
Ce partenariat positionne Dario pour générer des revenus récurrents à travers plusieurs canaux, y compris des programmes sponsorisés par les employeurs et des offres destinées directement aux consommateurs. La solution intégrée combine la gestion virtuelle des médecins avec l'expertise de Dario en matière de changement de comportement pour optimiser les résultats et le retour sur investissement pour les employeurs, tout en offrant un accès fluide aux soins pour les individus susceptibles de bénéficier le plus des médicaments GLP-1.
DarioHealth (Nasdaq: DRIO) hat eine strategische Zusammenarbeit mit MediOrbis angekündigt, um seine GLP-1-Verhaltensänderungslösung durch die Hinzufügung von Verschreibungsfunktionen zu verbessern. Diese Partnerschaft schafft ein umfassendes medizinisches Gewichtsreduktionsprogramm, das sich an Arbeitgeber und den direkten Endverbrauchermarkt richtet.
Die Zusammenarbeit kommt zu einem Zeitpunkt, an dem die Arbeitgeberdeckung für GLP-1-Medikamente zur Gewichtsreduktion wächst, wobei laut einer Umfrage von Mercer 44 % der großen Arbeitgeber gegenwärtig Adipositas-Medikamente abdecken. Die verbesserte Lösung zielt darauf ab, eine angemessene Verschreibung von Medikamenten sicherzustellen und gleichzeitig Unterstützung für Verhaltensänderungen zu bieten, um nachhaltige Gewichtsverlust-Ergebnisse zu erzielen.
Die Partnerschaft positioniert Dario, um wiederkehrende Einnahmen über mehrere Kanäle zu generieren, einschließlich arbeitgeberfinanzierter Programme und Direktangebote an Verbraucher. Die integrierte Lösung kombiniert das virtuelle Management von Ärzten mit Darios Expertise in Verhaltensänderungen, um Ergebnisse und ROI für Arbeitgeber zu optimieren, während sie gleichzeitig den Personen, die am ehesten von GLP-1-Medikamenten profitieren, einen nahtlosen Zugang zur Pflege ermöglicht.
- None.
- None.
New collaboration enhances Dario's comprehensive GLP-1 offering with virtual physician management to meet growing demand from employers covering weight-loss medications, opening new revenue streams in direct-to-consumer and pharma channels
Employer coverage of GLP-1 medications for weight loss continues to grow, with a recent survey from Mercer showing
Dario works with employers to support a wide range of GLP-1 benefits strategies by delivering the GLP-1 behavior change solution as required under plan design to help employees successfully lose weight and improve measurable results before, during and after the use of a GLP-1 medication. The addition of MediOrbis prescribing capabilities extends Dario's ability to optimize outcomes and ROI for employers by layering seamless access to care across the behavior change journey for people who are most likely to benefit from the addition of a GLP-1 medication.
"The GLP-1 market is rapidly expanding, but employers need more than access to medications—they need a solution that drives long-term health improvements and cost savings," said Steven Nelson, Chief Commercial Officer at Dario. "Our new collaboration with MediOrbis completes our end-to-end GLP-1 solution, enabling us to meet this demand by combining virtual prescribing with proven behavior change programs. We believe that this strategic move positions Dario to capture more opportunities in the employer and direct-to-consumer markets while delivering actionable insights to our pharma partners, opening new pathways for recurring revenue."
Dr. Omar Manejwala, Chief Medical Officer at Dario commented: "Achieving sustainable weight loss with GLP-1 medications requires more than just a prescription—it demands continuous, personalized support to maintain results. We believe that our collaboration with MediOrbis strengthens our ability to provide seamless, high-quality virtual care that complements our behavior change programs, ensuring members achieve meaningful health outcomes while employers see long-term value from their investment."
Dr. Jonathan Wiesen, Co – Founder and Chief Medical Officer of MediOrbis commented: "We are excited to collaborate with Dario to leverage digital care to address and manage obesity and other specialty and chronic illnesses, which are the most prevalent and resource-consumptive health conditions. This collaboration allows us to continue to seek to innovate and develop meaningful clinical programs that impact the health, productivity and well-being of employees worldwide."
About DarioHealth Corp.
DarioHealth Corp. (Nasdaq: DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Dario's platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.
Dario's user-centric platform offers people continuous and customized care for their health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results and making the right thing to do the easy thing to do.
Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care and consumers. To learn more about Dario and its digital health solutions, or for more information, visit http://dariohealth.com.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses the future market growth of GLP-1 medications for weight loss, the benefits to employers and patients resulting from the collaboration between the Company and MediOrbis, and the potential of the collaboration to position the Company to drive recurring revenue and expand its addressable market. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the
Logo: https://mma.prnewswire.com/media/1920436/3708722/DarioHealth_Logo.jpg
DarioHealth Corporate Contact
Mary Mooney
VP Marketing
mary@dariohealth.com
+1-312-593-4280
DarioHealth Investor Relations Contact
Kat Parrella
Investor Relations Manager
kat@dariohealth.com
+315-378-6922
View original content:SOURCE DarioHealth Corp.
FAQ
What does DarioHealth's collaboration with MediOrbis add to its GLP-1 solution?
What percentage of large employers currently cover GLP-1 medications for weight loss?
How will the MediOrbis partnership affect DRIO's revenue streams?
What is the main goal of DarioHealth's enhanced GLP-1 solution?
How does DRIO's GLP-1 solution benefit employers?
